Results 31 to 40 of about 43,499 (244)

Targeting DNA damage response deficiency in the treatment of breast cancer [PDF]

Zhongguo aizheng zazhi, 2022
DNA damage response (DDR) deficiency has been one of the emerging targets in treating breast cancer in recent years. The DDR pathway is essential for the identification, signal transduction and repair of DNA damage.
JIN Yizi, LIN Mingxi, ZHANG Jian
doaj   +3 more sources

The clinical development of inhibitors of poly(ADP-ribose) polymerase

Annals of Oncology, 2011
A number of inhibitors of DNA repair have been evaluated or are undergoing development as potential cancer treatments. Inhibitors of poly(ADP-ribose) polymerase (PARP) are of particular interest in treating hereditary breast cancers occurring in patients who are carriers of BRCA1 or BRCA2 mutations. In vitro PARP inhibitors are highly cytotoxic to cell
H, Calvert, A, Azzariti
openaire   +2 more sources

Pan-cancer landscape of homologous recombination deficiency

Nature Communications, 2020
Cancers deficient in homologous recombination can benefit from treatment with poly ADP-ribose polymerase (PARP) inhibitors. Here, the authors generated a classifier that can predict homologous recombination deficiency from genomic data and suggest ...
Luan Nguyen, John W. M. Martens, Arne Van Hoeck, Edwin Cuppen   +3 more
doaj   +1 more source

Background-Quenched Aggregation-Induced Emission through Electrostatic Interactions for the Detection of Poly(ADP-ribose) Polymerase-1 Activity

Molecules, 2023
Poly(ADP-ribose) polymerase-1 (PARP1) is a potential biomarker and therapeutic target for cancers that can catalyze the poly-ADP-ribosylation of nicotinamide adenine dinucleotide (NAD+) onto the acceptor proteins to form long poly(ADP-ribose) (PAR ...
Fengli Gao, Ruimin Zhao, Liping Huang, Xinyao Yi   +3 more
doaj   +1 more source

Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics [PDF]

Acta Pharmacologica Sinica, 2010
The year of 2005 was a watershed in the history of poly(ADP-ribose) polymerase (PARP) inhibitors due to the important findings of selective killing in BRCA-deficient cancers by PARP inhibition. The findings made PARP inhibition one of the most promising new therapeutic approaches to cancers, especially to those with specific defects.
Jin-xue, He, Chun-hao, Yang, Ze-hong, Miao   +2 more
openaire   +2 more sources

Poly-ADP-ribose polymerase (PARP) inhibitors and ovarian function

Biomedicine & Pharmacotherapy, 2023
Poly-ADP-ribose polymerase (PARP) plays an important role in DNA damage detection and repair. PARP inhibitors (PARPi) are a novel class of targeted agents used widely in the treatment of female cancer patients with BRCA mutations, including younger patients.
Jiajia, Li, Qingchao, Li, Lingyi, Zhang, Songling, Zhang, Yun, Dai   +4 more
openaire   +2 more sources

Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers

Clinical and Translational Radiation Oncology, 2020
Summary: PARP inhibitors have been shown to radiosensitize tumor cells in both in vitro and in vivo studies. This is a phase I study that aims to determine the safety, tolerability, and maximally tolerated dose of talazoparib, a PARP inhibitor, when ...
David S. Lakomy, Diana L. Urbauer, Shannon N. Westin, Lilie L. Lin   +3 more
doaj   +1 more source

Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond

Drugs in R&D, 2020
Genetic complexity and DNA damage repair defects are common in different cancer types and can induce tumor-specific vulnerabilities. Poly(ADP-ribose) polymerase (PARP) inhibitors exploit defects in the DNA repair pathway through synthetic lethality and ...
Stergios Boussios, Charlotte Abson, Michele Moschetta, Elie Rassy, Afroditi Karathanasi, Tahir Bhat, Faisal Ghumman, Matin Sheriff, Nicholas Pavlidis   +8 more
doaj   +1 more source

NADP+ is an endogenous PARP inhibitor in DNA damage response and tumor suppression

Nature Communications, 2019
Cancer cells respond differently to inhibitors of Poly (ADP-ribose) polymerase. Here the authors reveal that ovarian cancer cells with higher cellular NADP+ levels are more sensitive to clinically relevant PARP1 inhibitors and show that NADP+ act as an ...
Chunjing Bian, Chao Zhang, Tao Luo, Aditi Vyas, Shih-Hsun Chen, Chao Liu, Muzaffer Ahmad Kassab, Ying Yang, Mei Kong, Xiaochun Yu   +9 more
doaj   +1 more source

Expert Consensus on the Clinical Application of Poly ADP Ribose Polymerase Inhibitors in Breast Cancer (2025 Edition). [PDF]

Cancer Innov
This consensus, based on the latest evidence‐based medical data, provides guidance on the standardized application and safety management of PARP inhibitors in breast cancer treatment, aiming to serve as a reference for clinical practice. ABSTRACT Breast cancer represents a major threat to women's health in China.
Ma F, Xu B, China Anti‐Cancer Association Committee on Clinical Research of Anticancer Drugs, National Expert Committee on Monitoring Clinical Application of Antineoplastic Drugs, Breast Cancer Expert Committee of National Cancer Quality Control Center, Expert Committee on Chemotherapy Quality Control of Beijing Cancer Treatment Quality Control and Improvement Center.   +5 more
europepmc   +2 more sources